Pipeline

• Oral Treprostinil for PAH
• Beraprost-MR for PAH
• 3F8 MAb for Neuroblastoma
• Oral Treprostinil for PVD
• Aviptadil for PAH
• 8H9 MAb for Metastatic Brain Cancer
• IW001 for IPF and PGD
• Glycobiology Antiviral Agents

• We are developing an oral formulation of treprostinil (treprostinil diethanolamine). We are currently enrolling two clinical trials to evaluate the safety and efficacy of oral treprostinil in patients with PAH, FREEDOM-C2 and FREEDOM-M. The FREEDOM- C2 trial is a study of patients currently on approved background therapy using a PDE5 inhibitor, such as Revatio® or an ERA, such as Tracleer® or a combination of both. The FREEDOM-M trial is a study of patients who are not on any background therapy.
• Lung Rx, LLC has licensed the rights from Toray Industries, Inc., a Japanese company, to develop and market Beraprost Sodium Modified Release tablets (BPS-MR) for the treatment of Pulmonary Arterial Hypertension.
  BPS-MR has been demonstrated in various pharmacological studies to exhibit potent antiplatelet effects (inhibition of platelet aggregation and adhesion) and vasodilatory effects.
• The monoclonal anitbody 3F8 is a mouse lgG3 MAb which is currently used in an investigatinal setting for the treatment of neuroblastoma, a rare cancer of the sympathetic nervous system maining affecting children. It is the most common extracranical solid cancer in infants.
• We are currently enrolling patients in a Phase II study to investigate the effectiveness of oral treprostinil in reducing the frequency and severity of ulcers located on the fingers and toes of scleroderma patients.
• Lung Rx acquired the exclusive right to develop and market aviptadil for the treatment of PAH and other pulmonary diseases. A Phase II study of Aviptadil in PAH was recently completed.
• The monoclonal antibody 8H9 is a mouse IgG1 antibody with specificity for the B7H3 antigen. The 8H9 antibody is hight reactive with a range of human solid tumors, including human brain cancers.
• Lung Rx entered into a Development Agreement with ImmuneWorks to develop IW001, a purified bovine Type V Collagen oral solution for the treatment of IPF and PGD. We expect to commence human clinical testing of IW001 in 2010.
• This is a broad-spectrum antiviral drug platform using glycobiology molecules called iminosugars, which have shown activity against multiple viruses such as West Nile, influenza, dengue and Hepatitis C. The iminosugars cause misfolding of viral proteins, making the viruses non-infectious.

• Cardiovascular 
• Cancer 
• Pulmonary 
• Infectious Disease 

Click here for more information on our clinical trials